Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$925.34
-1.8%
$918.98
$661.85
▼
$1,072.75
$58.19B0.48352,063 shs248,893 shs
Biogen Inc. stock logo
BIIB
Biogen
$249.59
+1.0%
$236.18
$160.36
▼
$261.00
$36.89B0.11.21 million shs1.13 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$91.35
-1.8%
$113.53
$61.22
▼
$134.00
$10.41B0.921.99 million shs1.50 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$160.63
+0.8%
$190.87
$69.50
▼
$224.31
$34.74B1.442.82 million shs4.74 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
+0.08%-4.00%+8.32%-9.40%+3.00%
Biogen Inc. stock logo
BIIB
Biogen
-1.70%-1.34%+1.66%+14.00%+47.16%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-2.88%-7.58%-25.19%-13.99%+32.44%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-0.24%-9.59%-18.89%-23.89%+126.05%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$925.34
-1.8%
$918.98
$661.85
▼
$1,072.75
$58.19B0.48352,063 shs248,893 shs
Biogen Inc. stock logo
BIIB
Biogen
$249.59
+1.0%
$236.18
$160.36
▼
$261.00
$36.89B0.11.21 million shs1.13 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$91.35
-1.8%
$113.53
$61.22
▼
$134.00
$10.41B0.921.99 million shs1.50 million shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$160.63
+0.8%
$190.87
$69.50
▼
$224.31
$34.74B1.442.82 million shs4.74 million shs
10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
+0.08%-4.00%+8.32%-9.40%+3.00%
Biogen Inc. stock logo
BIIB
Biogen
-1.70%-1.34%+1.66%+14.00%+47.16%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-2.88%-7.58%-25.19%-13.99%+32.44%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-0.24%-9.59%-18.89%-23.89%+126.05%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
2.82
Moderate Buy$1,163.1825.70% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.67
Moderate Buy$255.452.35% Upside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.46
Hold$110.1720.60% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.92
Moderate Buy$262.7563.57% Upside

Current Analyst Ratings Breakdown

Latest HALO, ARGX, RVMD, and BIIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Biogen Inc. stock logo
BIIB
Biogen
Set Price Target$271.00
11/20/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Set Price Target$130.00
11/20/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Boost Price TargetNeutral$79.00 ➝ $81.00
11/20/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Reiterated RatingBuy$130.00
11/19/2026
Biogen Inc. stock logo
BIIB
Biogen
Set Price TargetBuy$270.00
11/18/2026
Biogen Inc. stock logo
BIIB
Biogen
Reiterated RatingBuy
11/17/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Reiterated RatingBuy$350.00
11/16/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Reiterated RatingBuy
11/16/2026
argenex SE stock logo
ARGX
argenex
Boost Price TargetOverweight$1,215.00 ➝ $1,350.00
11/13/2026
argenex SE stock logo
ARGX
argenex
Lower Price TargetOverweight$1,190.00 ➝ $1,130.00
11/13/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Lower Price TargetOverweight$272.00 ➝ $247.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$5.82B10.00$20.97 per share44.12$118.34 per share7.82
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.73$22.47 per share11.11$128.01 per share1.95
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.40B7.46$4.55 per share20.08($0.48) per share-190.31
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,000.27N/AN/A$11.10 per share14.47
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$1.29B$28.6632.2926.330.8831.66%47.70%40.12%N/A
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$2.34106.6615.662.853.37%9.38%5.69%2/5/2027 (Estimated)
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$316.89M$3.9323.249.320.3626.93%751.81%23.84%N/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$9.11N/AN/AN/AN/A-84.51%-51.97%N/A

Latest HALO, ARGX, RVMD, and BIIB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$2.30$2.39+$0.09$2.01$491.63 million$492.97 million
11/4/2026Q3 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.35-$1.90+$0.45-$1.90$25.58 million$197.56 million
10/28/2026Q3 2026
Biogen Inc. stock logo
BIIB
Biogen
$1.99$2.62+$0.63-$0.14$2.63 billion$2.80 billion
10/23/2026Q3 2026
argenex SE stock logo
ARGX
argenex
$7.44$7.80+$0.36$7.80N/A$1.75 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
5.12
4.89
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.95
1.37
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
13.50
3.88
3.60
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.44
8.36
8.34

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.50%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,86362.89 million61.36 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.82 million147.45 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
423114.01 million111.16 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
883216.29 million199.85 millionOptionable

Recent News About These Companies

Revolution Medicines (NASDAQ:RVMD) Shares Up 5.3% - What's Next?
Revolution Medicines (NASDAQ:RVMD) Earns Buy Rating from HC Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
argenex stock logo

argenex NASDAQ:ARGX

$925.34 -16.70 (-1.77%)
Closing price 03:59 PM Eastern
Extended Trading
$901.68 -23.66 (-2.56%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Biogen stock logo

Biogen NASDAQ:BIIB

$249.59 +2.46 (+1.00%)
Closing price 04:00 PM Eastern
Extended Trading
$248.14 -1.45 (-0.58%)
As of 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$91.35 -1.69 (-1.82%)
Closing price 04:00 PM Eastern
Extended Trading
$95.09 +3.74 (+4.09%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$160.63 +1.20 (+0.75%)
Closing price 03:58 PM Eastern
Extended Trading
$161.99 +1.36 (+0.85%)
As of 05:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.